Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03931291
Title APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Aprea Therapeutics AB
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

APR-246 + Azacitidine

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST